Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457917 | 0.91 | ADRB1 (0.71) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL11242572 | 0.90 | HTT (0.60) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL11246808 | 0.85 | CYP2D6 (0.65) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL23530 | 0.85 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Levobetaxolol SCHEMBL23532 | 0.85 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL4997902 | 0.85 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL23531 | 0.85 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL6512495 | 0.85 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Levobetaxolol SCHEMBL42795 | 0.84 | LMNA (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL42794 | 0.84 | LMNA (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308162-A1 | DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308162-A1 | DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY | AGER, PDE6B, PTGER1 | ADRB1 59/4885LMNA 781/4885CYP2D6 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.